Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAC + TC + TA + cyclophosphamide + doxorubicin + fluorouracil + cyclophosphamide + epirubicin + fluorouracil
- Development stage
- Unknown
- Lead developer
- Shandong Cancer Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This entry refers to a collection of standard neoadjuvant chemotherapy (NAC) regimens utilized in the Phase 3 BCSMANC (Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy) clinical trial. The regimens included are TAC (docetaxel, doxorubicin, and cyclophosphamide), TC (docetaxel and cyclophosphamide), TA (docetaxel and doxorubicin), FAC/CAF (cyclophosphamide, doxorubicin, and fluorouracil), and FEC/CEF (cyclophosphamide, epirubicin, and fluorouracil). These combinations consist of well-established cytotoxic agents that target various stages of DNA replication and cell division. The trial, conducted by Shandong Cancer Hospital and Institute, aimed to study the spatial and morphological patterns of tumor shrinkage using 3D pathological and MRI reconstruction to improve the precision of breast-conserving surgery in breast cancer patients.
- Other names
- TACTCTAFACFECCAFCEF
02
Targets
TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on TAC + TC + TA + cyclophosphamide + doxorubicin + fluorouracil + cyclophosphamide + epirubicin + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAC + TC + TA + cyclophosphamide + doxorubicin + fluorouracil + cyclophosphamide + epirubicin + fluorouracil.